DENVER, Feb. 08, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will host its Investor Day on Tuesday, February 27, 2024, in New York City at 9:00am ET.
InnovAge President and CEO Patrick Blair will host the event, along with several members of the Company’s executive team.
The event will be an opportunity to learn more about InnovAge’s business, including the Company’s operating platform, clinical model, and growth strategy, while providing the investment community with an opportunity to meet the Company’s executive team.
Registration instructions for analysts and institutional investors who would like to attend the event in person or for anyone else who would like to view the live webcast can be found here.
About InnovAge
InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of December 31, 2023, InnovAge served approximately 6,780 participants across 18 centers in five states. https://www.innovage.com/.
Investor Contact:
Ryan Kubota
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Lara Hazenfield
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.34 |
Daily Change: | -0.17 -3.09 |
Daily Volume: | 48,453 |
Market Cap: | US$723.640M |
September 23, 2025 September 09, 2025 February 04, 2025 November 05, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load